Publication: Vitamin K prophylaxis in the neonate by the oral route and its significance in reducing infant mortality and morbidity
Submitted Date
Received Date
Accepted Date
Issued Date
1986-12-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
01252208
eISSN
DOI
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-0022885575
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.69, No.SUPPL. 2 (1986), 56-61
Citation
P. B. Isarangkura, P. Bintadish, A. Tejavej, P. Siripoonya, R. Chulajata, G. M. Green, K. Chalermchandra (1986). Vitamin K prophylaxis in the neonate by the oral route and its significance in reducing infant mortality and morbidity. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/9790.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Vitamin K prophylaxis in the neonate by the oral route and its significance in reducing infant mortality and morbidity
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
Vitamin K in oral drops and intramuscular injection given at birth to Thai infants were compared to determine whether these routes and doses would influence prothrombin complex activity, mortality or morbidity at 0.5, 1 and 2 months of age. The infants were 321 normal fullterm babies born at Bangkok Adventist Hospital in 1983, exclusively breastfed during the study. Prothrombin complex (PC) was measured by the Owren capillary thrombotest method using a reagent from Nyegaard Co., Oslo. Vitamin K was given in single 1 or 2 mg oral doses, or 1 mg im, within 12 hours of delivery. Judging by the number of PC deficient children, the 1 mg im and 2 mg oral doses of vitamin K maintained clotting factors best at 2 months of age. All formulations were significantly better than no treatment at 1 month at age. No toxicity or side effects were seen. Vitamin K deficiency is a known cause of bleeding disorders, particularly fatal and handicapping intracranial hemorrhage in newborns, in developing countries where injections cannot be given by midwives. These inexpensive oral pediatric drops may provide a practical form of primary health care for routine vitamin K prophylaxis in newborns.